Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: Sources of sample bias

Dale McLerran, William E. Grizzle, Ziding Feng, William L. Bigbee, Lionel L. Banez, Lisa H. Cazares, Daniel W. Chan, Jose Diaz, Elzbieta Izbicka, Jacob Kagan, David E. Malehorn, Gunjan Malik, Denise Oelschlager, Alan Partin, Timothy Randolph, Nicole Rosenzweig, Shiv Srivastava, Sudhir Srivastava, Ian M. Thompson, Mark ThornquistDean Troyer, Yutaka Yasui, Zhen Zhang, Liu Zhu, O. John Semmes

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

BACKGROUND: This report and a companion report describe a validation of the ability of serum proteomic profiling via SELDI-TOF mass spectrometry to detect prostatic cancer. Details of this 3-stage process have been described. This report describes the development of the algorithm and results of the blinded test for stage 1. METHODS: We derived the decision algorithm used in this study from the analysis of serum samples from patients with prostate cancer (n = 181) and benign prostatic hyperplasia (BPH) (n = 143) and normal controls (n = 220). We also derived a validation test set from a separate, geographically diverse set of serum samples from 42 prostate cancer patients and 42 controls without prostate cancer. Aliquots were subjected to randomization and blinded analysis, and data from each laboratory site were subjected to the decision algorithm and decoded. RESULTS: Using the data collected from the validation test set, the decision algorithm was unsuccessful in separating cancer from controls with any predictive utility. Analysis of the experimental data revealed potential sources of bias. CONCLUSION: The ability of the decision algorithm to successfully differentiate between prostate cancer, BPH, and control samples using data derived from serum protein profiling was compromised by bias.

Original languageEnglish (US)
Pages (from-to)44-52
Number of pages9
JournalClinical Chemistry
Volume54
Issue number1
DOIs
StatePublished - Jan 1 2008

Fingerprint

Proteomics
Prostatic Neoplasms
Serum
Prostatic Hyperplasia
Random Allocation
Mass spectrometry
Blood Proteins
Mass Spectrometry
Neoplasms

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

McLerran, D., Grizzle, W. E., Feng, Z., Bigbee, W. L., Banez, L. L., Cazares, L. H., ... Semmes, O. J. (2008). Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: Sources of sample bias. Clinical Chemistry, 54(1), 44-52. https://doi.org/10.1373/clinchem.2007.091470

Analytical validation of serum proteomic profiling for diagnosis of prostate cancer : Sources of sample bias. / McLerran, Dale; Grizzle, William E.; Feng, Ziding; Bigbee, William L.; Banez, Lionel L.; Cazares, Lisa H.; Chan, Daniel W.; Diaz, Jose; Izbicka, Elzbieta; Kagan, Jacob; Malehorn, David E.; Malik, Gunjan; Oelschlager, Denise; Partin, Alan; Randolph, Timothy; Rosenzweig, Nicole; Srivastava, Shiv; Srivastava, Sudhir; Thompson, Ian M.; Thornquist, Mark; Troyer, Dean; Yasui, Yutaka; Zhang, Zhen; Zhu, Liu; Semmes, O. John.

In: Clinical Chemistry, Vol. 54, No. 1, 01.01.2008, p. 44-52.

Research output: Contribution to journalArticle

McLerran, D, Grizzle, WE, Feng, Z, Bigbee, WL, Banez, LL, Cazares, LH, Chan, DW, Diaz, J, Izbicka, E, Kagan, J, Malehorn, DE, Malik, G, Oelschlager, D, Partin, A, Randolph, T, Rosenzweig, N, Srivastava, S, Srivastava, S, Thompson, IM, Thornquist, M, Troyer, D, Yasui, Y, Zhang, Z, Zhu, L & Semmes, OJ 2008, 'Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: Sources of sample bias', Clinical Chemistry, vol. 54, no. 1, pp. 44-52. https://doi.org/10.1373/clinchem.2007.091470
McLerran, Dale ; Grizzle, William E. ; Feng, Ziding ; Bigbee, William L. ; Banez, Lionel L. ; Cazares, Lisa H. ; Chan, Daniel W. ; Diaz, Jose ; Izbicka, Elzbieta ; Kagan, Jacob ; Malehorn, David E. ; Malik, Gunjan ; Oelschlager, Denise ; Partin, Alan ; Randolph, Timothy ; Rosenzweig, Nicole ; Srivastava, Shiv ; Srivastava, Sudhir ; Thompson, Ian M. ; Thornquist, Mark ; Troyer, Dean ; Yasui, Yutaka ; Zhang, Zhen ; Zhu, Liu ; Semmes, O. John. / Analytical validation of serum proteomic profiling for diagnosis of prostate cancer : Sources of sample bias. In: Clinical Chemistry. 2008 ; Vol. 54, No. 1. pp. 44-52.
@article{8ceee5c1b11b44daa989b59b4e3392d3,
title = "Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: Sources of sample bias",
abstract = "BACKGROUND: This report and a companion report describe a validation of the ability of serum proteomic profiling via SELDI-TOF mass spectrometry to detect prostatic cancer. Details of this 3-stage process have been described. This report describes the development of the algorithm and results of the blinded test for stage 1. METHODS: We derived the decision algorithm used in this study from the analysis of serum samples from patients with prostate cancer (n = 181) and benign prostatic hyperplasia (BPH) (n = 143) and normal controls (n = 220). We also derived a validation test set from a separate, geographically diverse set of serum samples from 42 prostate cancer patients and 42 controls without prostate cancer. Aliquots were subjected to randomization and blinded analysis, and data from each laboratory site were subjected to the decision algorithm and decoded. RESULTS: Using the data collected from the validation test set, the decision algorithm was unsuccessful in separating cancer from controls with any predictive utility. Analysis of the experimental data revealed potential sources of bias. CONCLUSION: The ability of the decision algorithm to successfully differentiate between prostate cancer, BPH, and control samples using data derived from serum protein profiling was compromised by bias.",
author = "Dale McLerran and Grizzle, {William E.} and Ziding Feng and Bigbee, {William L.} and Banez, {Lionel L.} and Cazares, {Lisa H.} and Chan, {Daniel W.} and Jose Diaz and Elzbieta Izbicka and Jacob Kagan and Malehorn, {David E.} and Gunjan Malik and Denise Oelschlager and Alan Partin and Timothy Randolph and Nicole Rosenzweig and Shiv Srivastava and Sudhir Srivastava and Thompson, {Ian M.} and Mark Thornquist and Dean Troyer and Yutaka Yasui and Zhen Zhang and Liu Zhu and Semmes, {O. John}",
year = "2008",
month = "1",
day = "1",
doi = "10.1373/clinchem.2007.091470",
language = "English (US)",
volume = "54",
pages = "44--52",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "1",

}

TY - JOUR

T1 - Analytical validation of serum proteomic profiling for diagnosis of prostate cancer

T2 - Sources of sample bias

AU - McLerran, Dale

AU - Grizzle, William E.

AU - Feng, Ziding

AU - Bigbee, William L.

AU - Banez, Lionel L.

AU - Cazares, Lisa H.

AU - Chan, Daniel W.

AU - Diaz, Jose

AU - Izbicka, Elzbieta

AU - Kagan, Jacob

AU - Malehorn, David E.

AU - Malik, Gunjan

AU - Oelschlager, Denise

AU - Partin, Alan

AU - Randolph, Timothy

AU - Rosenzweig, Nicole

AU - Srivastava, Shiv

AU - Srivastava, Sudhir

AU - Thompson, Ian M.

AU - Thornquist, Mark

AU - Troyer, Dean

AU - Yasui, Yutaka

AU - Zhang, Zhen

AU - Zhu, Liu

AU - Semmes, O. John

PY - 2008/1/1

Y1 - 2008/1/1

N2 - BACKGROUND: This report and a companion report describe a validation of the ability of serum proteomic profiling via SELDI-TOF mass spectrometry to detect prostatic cancer. Details of this 3-stage process have been described. This report describes the development of the algorithm and results of the blinded test for stage 1. METHODS: We derived the decision algorithm used in this study from the analysis of serum samples from patients with prostate cancer (n = 181) and benign prostatic hyperplasia (BPH) (n = 143) and normal controls (n = 220). We also derived a validation test set from a separate, geographically diverse set of serum samples from 42 prostate cancer patients and 42 controls without prostate cancer. Aliquots were subjected to randomization and blinded analysis, and data from each laboratory site were subjected to the decision algorithm and decoded. RESULTS: Using the data collected from the validation test set, the decision algorithm was unsuccessful in separating cancer from controls with any predictive utility. Analysis of the experimental data revealed potential sources of bias. CONCLUSION: The ability of the decision algorithm to successfully differentiate between prostate cancer, BPH, and control samples using data derived from serum protein profiling was compromised by bias.

AB - BACKGROUND: This report and a companion report describe a validation of the ability of serum proteomic profiling via SELDI-TOF mass spectrometry to detect prostatic cancer. Details of this 3-stage process have been described. This report describes the development of the algorithm and results of the blinded test for stage 1. METHODS: We derived the decision algorithm used in this study from the analysis of serum samples from patients with prostate cancer (n = 181) and benign prostatic hyperplasia (BPH) (n = 143) and normal controls (n = 220). We also derived a validation test set from a separate, geographically diverse set of serum samples from 42 prostate cancer patients and 42 controls without prostate cancer. Aliquots were subjected to randomization and blinded analysis, and data from each laboratory site were subjected to the decision algorithm and decoded. RESULTS: Using the data collected from the validation test set, the decision algorithm was unsuccessful in separating cancer from controls with any predictive utility. Analysis of the experimental data revealed potential sources of bias. CONCLUSION: The ability of the decision algorithm to successfully differentiate between prostate cancer, BPH, and control samples using data derived from serum protein profiling was compromised by bias.

UR - http://www.scopus.com/inward/record.url?scp=38749109634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38749109634&partnerID=8YFLogxK

U2 - 10.1373/clinchem.2007.091470

DO - 10.1373/clinchem.2007.091470

M3 - Article

C2 - 17981926

AN - SCOPUS:38749109634

VL - 54

SP - 44

EP - 52

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 1

ER -